Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]

Hoggatt J, Tate TA, Pelus LM. Int J Nanomed. 2015;10:2647–2652.In this article, Lipegfilgrastim was referred to as a "long-acting biosimilar filgrastim". The term "biosimilar" was used too broadly in this case, as Lipegfilgrastim was not approved under t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hoggatt J, Tate TA, Pelus LM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/c6fde9992f154241970ca9e958d79a30
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c6fde9992f154241970ca9e958d79a30
record_format	dspace
spelling	oai:doaj.org-article:c6fde9992f154241970ca9e958d79a302021-12-02T07:21:41ZRole of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]1178-2013https://doaj.org/article/c6fde9992f154241970ca9e958d79a302015-08-01T00:00:00Zhttp://www.dovepress.com/corrigendum-role-of-lipegfilgrastim-in-the-management-of-chemothe-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Hoggatt J, Tate TA, Pelus LM. Int J Nanomed. 2015;10:2647–2652.In this article, Lipegfilgrastim was referred to as a "long-acting biosimilar filgrastim". The term "biosimilar" was used too broadly in this case, as Lipegfilgrastim was not approved under the biosimilar classification by the EMA. Rather, lipegfilgrastim has an active substance that is similar to filgrastim, with similar pharmacokinetics, receptor binding affinity, safety and efficacy as pegfilgrastim.Read the original article.Hoggatt JTate TAPelus LMDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2015, Iss default, Pp 5421-5422 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Hoggatt J Tate TA Pelus LM Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]
description	Hoggatt J, Tate TA, Pelus LM. Int J Nanomed. 2015;10:2647–2652.In this article, Lipegfilgrastim was referred to as a "long-acting biosimilar filgrastim". The term "biosimilar" was used too broadly in this case, as Lipegfilgrastim was not approved under the biosimilar classification by the EMA. Rather, lipegfilgrastim has an active substance that is similar to filgrastim, with similar pharmacokinetics, receptor binding affinity, safety and efficacy as pegfilgrastim.Read the original article.
format	article
author	Hoggatt J Tate TA Pelus LM
author_facet	Hoggatt J Tate TA Pelus LM
author_sort	Hoggatt J
title	Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]
title_short	Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]
title_full	Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]
title_fullStr	Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]
title_full_unstemmed	Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]
title_sort	role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [corrigendum]
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/c6fde9992f154241970ca9e958d79a30
work_keys_str_mv	AT hoggattj roleoflipegfilgrastiminthemanagementofchemotherapyinducedneutropeniacorrigendum AT tateta roleoflipegfilgrastiminthemanagementofchemotherapyinducedneutropeniacorrigendum AT peluslm roleoflipegfilgrastiminthemanagementofchemotherapyinducedneutropeniacorrigendum
_version_	1718399479774707712

Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]

Ejemplares similares